Investigation into the use of plasma NT-proBNP concentration to screen for feline hypertrophic cardiomyopathy

Adonia Hsu, Mark D Kittleson, Anna Paling

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: To evaluate the utility of feline NT-proBNP plasma concentration [NT-proBNP] as a screening tool for cats with subclinical hypertrophic cardiomyopathy (HCM). Animals, materials and methods: Forty adult Maine Coon or Maine Coon crossbred cats from the feline HCM research colony at the University of California, Davis were studied. All cats had previously been genotyped as heterozygous or negative for the A31P myosin binding protein C (MYBPC) mutation. Echocardiograms were performed to assess the severity of HCM in each cat. Blood samples were collected for evaluation of [NT-proBNP]. Results: In these cats with severe HCM, [NT-proBNP] was significantly elevated (P < 0.0001) when compared to all other groups of cats and an [NT-proBNP] > 44pmol/L accurately predicted the presence of severe HCM. However, [NT-proBNP] was not increased in cats with moderate or equivocal HCM when compared to normal cats. Cats heterozygous for the MYBPC mutation had a significantly elevated [NT-proBNP] when compared to cats without the A31P mutation (P = 0.028). Conclusions: Measurement of [NT-proBNP] has a high sensitivity and specificity as a means of detecting severe HCM in cats, but it is not sensitive for the identification of moderate HCM as judged by the evaluation of Maine Coon and Maine Coon cross cats in our colony. Consequently, we conclude that this test cannot be used to screen cats for the presence of mild to moderate HCM.

Original languageEnglish (US)
JournalJournal of Veterinary Cardiology
Volume11
Issue numberSUPPL. 1
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Hypertrophic Cardiomyopathy
cardiomyopathy
Felidae
Cats
cats
Mutation
myosin
pro-brain natriuretic peptide (1-76)
mutation
binding proteins
crossbreds

Keywords

  • BNP
  • Cat
  • Hypertrophic cardiomyopathy
  • Natriuretic peptide
  • NT-proBNP

ASJC Scopus subject areas

  • Physiology
  • veterinary(all)

Cite this

Investigation into the use of plasma NT-proBNP concentration to screen for feline hypertrophic cardiomyopathy. / Hsu, Adonia; Kittleson, Mark D; Paling, Anna.

In: Journal of Veterinary Cardiology, Vol. 11, No. SUPPL. 1, 05.2009.

Research output: Contribution to journalArticle

@article{01747358bc214910a16faa8120de32c3,
title = "Investigation into the use of plasma NT-proBNP concentration to screen for feline hypertrophic cardiomyopathy",
abstract = "Objective: To evaluate the utility of feline NT-proBNP plasma concentration [NT-proBNP] as a screening tool for cats with subclinical hypertrophic cardiomyopathy (HCM). Animals, materials and methods: Forty adult Maine Coon or Maine Coon crossbred cats from the feline HCM research colony at the University of California, Davis were studied. All cats had previously been genotyped as heterozygous or negative for the A31P myosin binding protein C (MYBPC) mutation. Echocardiograms were performed to assess the severity of HCM in each cat. Blood samples were collected for evaluation of [NT-proBNP]. Results: In these cats with severe HCM, [NT-proBNP] was significantly elevated (P < 0.0001) when compared to all other groups of cats and an [NT-proBNP] > 44pmol/L accurately predicted the presence of severe HCM. However, [NT-proBNP] was not increased in cats with moderate or equivocal HCM when compared to normal cats. Cats heterozygous for the MYBPC mutation had a significantly elevated [NT-proBNP] when compared to cats without the A31P mutation (P = 0.028). Conclusions: Measurement of [NT-proBNP] has a high sensitivity and specificity as a means of detecting severe HCM in cats, but it is not sensitive for the identification of moderate HCM as judged by the evaluation of Maine Coon and Maine Coon cross cats in our colony. Consequently, we conclude that this test cannot be used to screen cats for the presence of mild to moderate HCM.",
keywords = "BNP, Cat, Hypertrophic cardiomyopathy, Natriuretic peptide, NT-proBNP",
author = "Adonia Hsu and Kittleson, {Mark D} and Anna Paling",
year = "2009",
month = "5",
doi = "10.1016/j.jvc.2009.02.005",
language = "English (US)",
volume = "11",
journal = "Journal of Veterinary Cardiology",
issn = "1760-2734",
publisher = "Elsevier",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Investigation into the use of plasma NT-proBNP concentration to screen for feline hypertrophic cardiomyopathy

AU - Hsu, Adonia

AU - Kittleson, Mark D

AU - Paling, Anna

PY - 2009/5

Y1 - 2009/5

N2 - Objective: To evaluate the utility of feline NT-proBNP plasma concentration [NT-proBNP] as a screening tool for cats with subclinical hypertrophic cardiomyopathy (HCM). Animals, materials and methods: Forty adult Maine Coon or Maine Coon crossbred cats from the feline HCM research colony at the University of California, Davis were studied. All cats had previously been genotyped as heterozygous or negative for the A31P myosin binding protein C (MYBPC) mutation. Echocardiograms were performed to assess the severity of HCM in each cat. Blood samples were collected for evaluation of [NT-proBNP]. Results: In these cats with severe HCM, [NT-proBNP] was significantly elevated (P < 0.0001) when compared to all other groups of cats and an [NT-proBNP] > 44pmol/L accurately predicted the presence of severe HCM. However, [NT-proBNP] was not increased in cats with moderate or equivocal HCM when compared to normal cats. Cats heterozygous for the MYBPC mutation had a significantly elevated [NT-proBNP] when compared to cats without the A31P mutation (P = 0.028). Conclusions: Measurement of [NT-proBNP] has a high sensitivity and specificity as a means of detecting severe HCM in cats, but it is not sensitive for the identification of moderate HCM as judged by the evaluation of Maine Coon and Maine Coon cross cats in our colony. Consequently, we conclude that this test cannot be used to screen cats for the presence of mild to moderate HCM.

AB - Objective: To evaluate the utility of feline NT-proBNP plasma concentration [NT-proBNP] as a screening tool for cats with subclinical hypertrophic cardiomyopathy (HCM). Animals, materials and methods: Forty adult Maine Coon or Maine Coon crossbred cats from the feline HCM research colony at the University of California, Davis were studied. All cats had previously been genotyped as heterozygous or negative for the A31P myosin binding protein C (MYBPC) mutation. Echocardiograms were performed to assess the severity of HCM in each cat. Blood samples were collected for evaluation of [NT-proBNP]. Results: In these cats with severe HCM, [NT-proBNP] was significantly elevated (P < 0.0001) when compared to all other groups of cats and an [NT-proBNP] > 44pmol/L accurately predicted the presence of severe HCM. However, [NT-proBNP] was not increased in cats with moderate or equivocal HCM when compared to normal cats. Cats heterozygous for the MYBPC mutation had a significantly elevated [NT-proBNP] when compared to cats without the A31P mutation (P = 0.028). Conclusions: Measurement of [NT-proBNP] has a high sensitivity and specificity as a means of detecting severe HCM in cats, but it is not sensitive for the identification of moderate HCM as judged by the evaluation of Maine Coon and Maine Coon cross cats in our colony. Consequently, we conclude that this test cannot be used to screen cats for the presence of mild to moderate HCM.

KW - BNP

KW - Cat

KW - Hypertrophic cardiomyopathy

KW - Natriuretic peptide

KW - NT-proBNP

UR - http://www.scopus.com/inward/record.url?scp=67349276406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349276406&partnerID=8YFLogxK

U2 - 10.1016/j.jvc.2009.02.005

DO - 10.1016/j.jvc.2009.02.005

M3 - Article

C2 - 19395334

AN - SCOPUS:67349276406

VL - 11

JO - Journal of Veterinary Cardiology

JF - Journal of Veterinary Cardiology

SN - 1760-2734

IS - SUPPL. 1

ER -